119 related articles for article (PubMed ID: 12182847)
41. 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.
Mesguiche V; Parsons RJ; Arris CE; Bentley J; Boyle FT; Curtin NJ; Davies TG; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Jewsbury P; Johnson LN; Newell DR; Noble ME; Wang LZ; Hardcastle IR
Bioorg Med Chem Lett; 2003 Jan; 13(2):217-22. PubMed ID: 12482427
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and biological activities of C-2, N-9 substituted 6-benzylaminopurine derivatives as cyclin-dependent kinase inhibitor.
Oh CH; Lee SC; Lee KS; Woo ER; Hong CY; Yang BS; Baek DJ; Cho JH
Arch Pharm (Weinheim); 1999 Jun; 332(6):187-90. PubMed ID: 10399486
[TBL] [Abstract][Full Text] [Related]
43. Under arrest at atomic resolution.
Morgan DO
Nature; 1996 Jul; 382(6589):295-6. PubMed ID: 8684452
[No Abstract] [Full Text] [Related]
44. CDK2/cyclinA inhibitors: targeting the cyclinA recruitment site with small molecules derived from peptide leads.
Castanedo G; Clark K; Wang S; Tsui V; Wong M; Nicholas J; Wickramasinghe D; Marsters JC; Sutherlin D
Bioorg Med Chem Lett; 2006 Mar; 16(6):1716-20. PubMed ID: 16384702
[TBL] [Abstract][Full Text] [Related]
45. Structural studies on phospho-CDK2/cyclin A bound to nitrate, a transition state analogue: implications for the protein kinase mechanism.
Cook A; Lowe ED; Chrysina ED; Skamnaki VT; Oikonomakos NG; Johnson LN
Biochemistry; 2002 Jun; 41(23):7301-11. PubMed ID: 12044161
[TBL] [Abstract][Full Text] [Related]
46. Beta-carbolines as specific inhibitors of cyclin-dependent kinases.
Song Y; Wang J; Teng SF; Kesuma D; Deng Y; Duan J; Wang JH; Qi RZ; Sim MM
Bioorg Med Chem Lett; 2002 Apr; 12(7):1129-32. PubMed ID: 11909733
[TBL] [Abstract][Full Text] [Related]
47. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists.
Chen YN; Sharma SK; Ramsey TM; Jiang L; Martin MS; Baker K; Adams PD; Bair KW; Kaelin WG
Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4325-9. PubMed ID: 10200261
[TBL] [Abstract][Full Text] [Related]
48. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Fåhraeus R; Laín S; Ball KL; Lane DP
Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
[TBL] [Abstract][Full Text] [Related]
49. Delta MEKK3:ER* activation induces a p38 alpha/beta 2-dependent cell cycle arrest at the G2 checkpoint.
Garner AP; Weston CR; Todd DE; Balmanno K; Cook SJ
Oncogene; 2002 Nov; 21(53):8089-104. PubMed ID: 12444545
[TBL] [Abstract][Full Text] [Related]
50. Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics.
Schoepfer J; Fretz H; Chaudhuri B; Muller L; Seeber E; Meijer L; Lozach O; Vangrevelinghe E; Furet P
J Med Chem; 2002 Apr; 45(9):1741-7. PubMed ID: 11960485
[TBL] [Abstract][Full Text] [Related]
51. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
Orend G; Hunter T; Ruoslahti E
Oncogene; 1998 May; 16(20):2575-83. PubMed ID: 9632134
[TBL] [Abstract][Full Text] [Related]
52. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity.
Fotedar R; Fitzgerald P; Rousselle T; Cannella D; Dorée M; Messier H; Fotedar A
Oncogene; 1996 May; 12(10):2155-64. PubMed ID: 8668341
[TBL] [Abstract][Full Text] [Related]
53. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
David-Pfeuty T
Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
[TBL] [Abstract][Full Text] [Related]
54. Chemical inhibitors of cyclin-dependent kinases.
Meijer L; Kim SH
Methods Enzymol; 1997; 283():113-28. PubMed ID: 9251015
[No Abstract] [Full Text] [Related]
55. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases.
Hoessel R; Leclerc S; Endicott JA; Nobel ME; Lawrie A; Tunnah P; Leost M; Damiens E; Marie D; Marko D; Niederberger E; Tang W; Eisenbrand G; Meijer L
Nat Cell Biol; 1999 May; 1(1):60-7. PubMed ID: 10559866
[TBL] [Abstract][Full Text] [Related]
56. Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching.
Furet P; Meyer T; Mittl P; Fretz H
J Comput Aided Mol Des; 2001 May; 15(5):489-95. PubMed ID: 11394741
[TBL] [Abstract][Full Text] [Related]
57. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.
Bramson HN; Corona J; Davis ST; Dickerson SH; Edelstein M; Frye SV; Gampe RT; Harris PA; Hassell A; Holmes WD; Hunter RN; Lackey KE; Lovejoy B; Luzzio MJ; Montana V; Rocque WJ; Rusnak D; Shewchuk L; Veal JM; Walker DH; Kuyper LF
J Med Chem; 2001 Dec; 44(25):4339-58. PubMed ID: 11728181
[TBL] [Abstract][Full Text] [Related]
58. 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases.
Misra RN; Rawlins DB; Xiao HY; Shan W; Bursuker I; Kellar KA; Mulheron JG; Sack JS; Tokarski JS; Kimball SD; Webster KR
Bioorg Med Chem Lett; 2003 Mar; 13(6):1133-6. PubMed ID: 12643928
[TBL] [Abstract][Full Text] [Related]
59. Cdk2 activity is dispensable for the onset of DNA replication during the first mitotic cycles of the sea urchin early embryo.
Moreau JL; Marques F; Barakat A; Schatt P; Lozano JC; Peaucellier G; Picard A; Genevière AM
Dev Biol; 1998 Aug; 200(2):182-97. PubMed ID: 9705226
[TBL] [Abstract][Full Text] [Related]
60. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
